NCT03007823 is a Phase 1, PHASE2 clinical trial of High-activity natural killer in Melanoma, sponsored by Fuda Cancer Hospital, Guangzhou.

Who is sponsoring NCT03007823?

NCT03007823 is sponsored by Fuda Cancer Hospital, Guangzhou.

What drugs are being tested in NCT03007823?

Interventions in NCT03007823: High-activity natural killer.

Is NCT03007823 still recruiting?

NCT03007823 is currently completed. Last updated 12 September 2019.

Last reviewed 2019-09-12 · How we verify

NCT03007823

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

High-activity Natural Killer Immunotherapy for Small Metastases of Melanoma

Completed Phase 1, PHASE2 Last updated 12 September 2019

What this trial tests

Phase 1, PHASE2 trial testing High-activity natural killer in Melanoma in 20 participants. Completed in 1 June 2019.

Timeline

1 December 2016

Primary endpoint
1 December 2017

1 June 2019

Quick facts

Lead sponsor	Fuda Cancer Hospital, Guangzhou
Phase	Phase 1, PHASE2
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	20
Start date	1 December 2016
Primary completion	1 December 2017
Estimated completion	1 June 2019
Sites	1 location across China

Drugs / interventions tested

High-activity natural killer — full drug profile →

Conditions studied

Melanoma — all drugs for Melanoma →

Sponsor

Fuda Cancer Hospital, Guangzhou

Who can join

Adults 30 to 60, any sex, with Melanoma. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The aim of this study is the safety and efficacy of high-activity natural killer immunotherapy to small metastases of melanoma.

Publications & conference data

6 peer-reviewed publications reference this trial (live from Europe PMC):

Targeting NK Cells to Enhance Melanoma Response to Immunotherapies.
Lee H, Da Silva IP, Palendira U, Scolyer RA, et al · · 2021 · cited 33× · PMID 33802954 · DOI 10.3390/cancers13061363
Precision Medicine and Melanoma: Multi-Omics Approaches to Monitoring the Immunotherapy Response.
Valenti F, Falcone I, Ungania S, Desiderio F, et al · · 2021 · cited 32× · PMID 33917181 · DOI 10.3390/ijms22083837
Adoptive NK Cell Therapy: A Promising Treatment Prospect for Metastatic Melanoma.
van Vliet AA, Georgoudaki AM, Raimo M, de Gruijl TD, et al · · 2021 · cited 26× · PMID 34572949 · DOI 10.3390/cancers13184722
NK Cell Plasticity in Cancer.
Liu S, Dhar P, Wu JD. · · 2019 · cited 26× · PMID 31546818 · DOI 10.3390/jcm8091492
Liquid Biopsy in Melanoma: Significance in Diagnostics, Prediction and Treatment Monitoring.
Kamińska P, Buszka K, Zabel M, Nowicki M, et al · · 2021 · cited 23× · PMID 34575876 · DOI 10.3390/ijms22189714
Lipid nanoparticle-mediated RNA delivery for immune cell modulation.
Kim EH, Teerdhala SV, Padilla MS, Joseph RA, et al · · 2024 · cited 19× · PMID 39279550 · DOI 10.1002/eji.202451008

Verify or expand the search:

Other trials of High-activity natural killer

Trials testing the same drug.

NCT03008330 — High-activity Natural Killer Immunotherapy for Small Metastases of Tongue Cancer · Phase 1, PHASE2 · completed
NCT03008499 — High-activity Natural Killer Immunotherapy for Small Metastases of Colorectal Cancer · Phase 1, PHASE2 · completed
NCT03008304 — High-activity Natural Killer Immunotherapy for Small Metastases of Pancreatic Cancer · Phase 1, PHASE2 · completed
NCT03007836 — High-activity Natural Killer Immunotherapy for Small Metastases of Nasopharyngeal Cancer · Phase 1, PHASE2 · completed

Other recruiting trials for Melanoma

Currently open trials in the same condition.

NCT07524114 — Study of High-Precision Evaluation of Molecular ResiduaL Disease Through a PlatfOrm for Cancer TracKing and Interception · recruiting
NCT07224425 — A Study in People With Advanced Cancer (Solid Tumours) to Test Different Doses of BI 3810944 and to Find Out Whether it · Phase 1 · recruiting
NCT07285044 — The Cancer Connected Access and Remote Expertise Beyond Walls Program to Provide In-Home Cancer Treatment and Improve Tr · Phase 2 · recruiting
NCT07225036 — Promoting Immunotherapy Efficacy With Low-Dose Liver RT · NA · recruiting
NCT07379138 — Studying Quality of Life Inclusive of Mental Health and Cognitive Behavioral Therapy for Cancer Distress for the Improve · NA · recruiting

Other Fuda Cancer Hospital, Guangzhou trials

Trials by the same sponsor.

NCT04393220 — Combination of PD-1 and VEGFR-2 Blockade for Advanced Hepatocellular Carcinoma · Phase 2 · completed
NCT03673137 — Phase II/III of Randomized Controlled Clinical Research on IRE Synchronous Chemotherapy for LAPC · Phase 2, PHASE3 · completed
NCT03976206 — Very Small Embryonic-like Stem Cells for Facial Skin Antiaging · Phase 1, PHASE2 · withdrawn
NCT03975101 — Very Small Embryonic-like Stem Cells for Knee Osteoarthritis · Phase 1, PHASE2 · withdrawn
NCT03985462 — Very Small Embryonic-like Stem Cells for Ovary · Phase 1, PHASE2 · withdrawn

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03007823 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Fuda Cancer Hospital, Guangzhou
Last refreshed: 12 September 2019

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03007823.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing